VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.
Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).
VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.
What if you could identify high risk patients at the earliest stage of their cardiovascular disease?
VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.
Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.

The POC testing market is set to reach $40 billion by 2022.

VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.

Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).

VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.

What if you could identify high risk patients at the earliest stage of their cardiovascular disease?

VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.

Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.

The POC testing market is set to reach $40 billion by 2022.

The StiffnoGraph is our innovative point-of-care device that estimates arterial stiffness within 2 minutes. Arterial stiffness is a major risk factor for cardiovascular disease. Early detection can lead to better prevention and treatment options.

The StiffnoGraph has a clinical evaluation report, is CE/MDD certified and is protected by patent application WO2016/131993 A2.

This revolutionary device enables healthcare providers to quickly estimate arterial stiffness and to estimate the risk of vitamin K insufficiency in combination with the Vermeer Index. Both arterial stiffness and insufficient intake of vitamin K are risk factors for cardiovascular disease. Arterial stiffness increases the risk of hypertension, myocardial infarction, heart failure, stroke and chronic kidney disease amongst others. Early detection can help in better prevention and treatment.

The StiffnoGraph is intended to be used by healthcare professionals, such as general practitioners, ortho-molecular practitioners, sports physicians, naturopaths, alternative medicine practitioners, dieticians and physiotherapists, as a first screening tool in the cardiovascular risk assessment of their clients.

The StiffnoGraph has been tested in a clinical study approved by the Dutch Medical Ethics Committee. The results are reproducible and show a good correlation with Pulse Wave Velocity, the current standard measurement of arterial stiffness.

 

Advantages of the StiffnoGraph:

  • High accuracy
  • Handheld, easy to carry
  • Robust and reliable
  • User-friendly, non-invasive
  • Operator independent, no training required
  • Fast throughput (screening) of patients
  • Multiple measurements with one device

Head office:
Oxfordlaan 55
6229 EV Maastricht
The Netherlands
T: +31 (0)43 388 5926

Laboratories:
Oxfordlaan 70
6229 EV Maastricht
The Netherlands
E: info@vitak.com